Skip to main content
. 2019 Jan 15;38:20. doi: 10.1186/s13046-018-0995-9

Table 1.

Correlation between FGF9 expression and clinicopathological parameters of gastric adenocarcinomas

Features N PTCAF-FGF9 expression(%) p value PT-FGF9 expression(%) p value N LNCAF-FGF9 expression(%) p value LNT-FGF9 expression(%) p value
low high low high low high low high
Total 160 112(70.0) 48(30.0) 141(88.1) 19(11.9) 106 72(67.9) 34(32.1) 93(87.7) 13(12.3)
Age
  < 60 54 42(77.8) 12(22.2) 0.125 53(98.1) 1(1.9) 0.005* 38 30(79.0) 8(21.0) 0.069 36(94.7) 2(5.3) 0.129
  ≥60 106 70(66.0) 36(34.0) 88(83.0) 18(17.0) 68 42(61.8) 26(38.2) 57(83.8) 11(16.2)
sex
  male 115 83(72.2) 32(27.8) 0.337 100(87.0) 15(13.0) 0.465 75 50(66.7) 25(33.3) 0.666 63(84.0) 12(16.0) 0.102
  female 45 29(64.4) 16(39.6) 41(91.1) 4(8.9) 31 22(71.0) 9(29.0) 30(96.8) 1(3.2)
tumor size
  < 5 57 45(79.0) 12(21.0) 0.066 53(93.0) 4(7.0) 0.158 38 27(71.1) 11(28.9) 0.606 32(84.2) 6(15.8) 0.408
  ≥ 5 103 67(65.0) 36(35.0) 88(85.4) 15(14.6) 68 45(66.2) 23(33.8) 61(89.7) 7(10.3)
Location
 GEJ-Cardia 24 15(62.5) 9(37.5) 0.029* 22(91.7) 2(8.3) 0.392 18 9(50.0) 9(50.0) 0.113 16(88.9) 2(11.1) 1.000
 Fundus-Body 41 30(73.2) 11(26.8) 38(92.7) 3(7.3) 28 22(78.6) 6(21.4) 25(89.3) 3(10.7)
 Antrum-Pylorus 87 65(74.7) 22(25.3) 75(86.2) 12(13.8) 57 40(70.2) 17(29.8) 49(86.0) 8(14.0)
 Remnant+ multi-sites 8 2(25.0) 6(75.0) 6(75.0) 2(25.0) 3 1(33.3) 2(66.7) 3(100) 0(0)
Differentiation
 well-moderate 25 16(64.0) 9(36.0) 0.476 21(84.0) 4(16.0) 0.503 16 7(43.8) 9(56.2) 0.025* 13(81.3) 3(18.7) 0.411
 poor 135 96(71.1) 39(28.9) 120(88.9) 15(11.1) 90 65(72.2) 25(27.8) 80(88.9) 10(11.1)
Lauren type
 intestinal 68 49(72.1) 19 (27.9) 0.625 57(83.8) 11(16.2) 0.148 46 25(54.4) 21(45.6) 0.009* 37(80.4) 9(19.6) 0.045*
 diffuse+mixed 92 63(68.5) 29(31.5) 84(91.3) 8(8.7) 60 47(78.3) 13(21.7) 56(93.3) 4(6.7)
pT stage
 T1 + T2 17 14(82.4) 3(17.6) 0.240 17(100) 0(0) 0.226 12 9(75.0) 3(25.0) 0.577 11(91.7) 1(8.3) 1.000
 T3 + T4 143 98(68.5) 45(31.5) 124(86.7) 19(13.3) 94 63(67.0) 31(33.0) 82(87.2) 12(12.8)
pN stage
  N0 31 18(58.1) 13(41.9) 0.407 28(90.3) 3(9.7) 0.792 / / / / / /
  N1 35 26(74.3) 9(25.7) 29(82.9) 6(17.1) 20 16(80.0) 4(20.0) 0.175 17(85.0) 3(15.0) 0.599
  N2 29 22(75.9) 7(24.1) 26(89.7) 3(10.3) 24 13(54.2) 11(45.8) 20(83.3) 4(16.7)
  N3 65 46(70.8) 19(29.2) 58(89.2) 7(10.8) 62 43(69.4) 19(30.6) 56(90.3) 6(9.7)
M stage
  M0 157 110(70.1) 47(29.9) 1.000 139(88.5) 18(11.5) 0.317 103 70(68.0) 33(32.0) 1.000 90(87.4) 13(12.6) 1.000
  M1 3 2(66.7) 1(33.3) 2(66.7) 1(33.3) 3 2(66.7) 1(33.3) 3(100) 0(0)
TNM stage
 I + II 63 42(66.7) 21(33.3) 0.458 55(87.3) 8(12.7) 0.795 20 14(70.0) 6(30.0) 0.825 16(80.0) 4(20.0) 0.262
 III + IV 97 70(72.2) 27(27.8) 86(88.1) 11(11.9) 86 58(67.4) 28(32.6) 77(89.5) 9(10.5)

*p < 0.05